138 related articles for article (PubMed ID: 36635950)
1. Atezolizumab induced new-onset type 1 diabetes mellitus.
de Carlos J; Zabalza L; Garcia J; Marti M; Ayarza-Marien X; Yoldi J
J Oncol Pharm Pract; 2023 Jul; 29(5):1268-1270. PubMed ID: 36635950
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
3. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
[TBL] [Abstract][Full Text] [Related]
4. Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature.
Hickmott L; De La Peña H; Turner H; Ahmed F; Protheroe A; Grossman A; Gupta A
Target Oncol; 2017 Apr; 12(2):235-241. PubMed ID: 28255845
[TBL] [Abstract][Full Text] [Related]
5. Atezolizumab-induced type 1 diabetes mellitus in a patient with metastatic renal cell carcinoma.
Rahman W; Conley A; Silver KD
BMJ Case Rep; 2020 Jul; 13(7):. PubMed ID: 32616532
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.
de Filette JMK; Pen JJ; Decoster L; Vissers T; Bravenboer B; Van der Auwera BJ; Gorus FK; Roep BO; Aspeslagh S; Neyns B; Velkeniers B; Kharagjitsingh AV
Eur J Endocrinol; 2019 Sep; 181(3):363-374. PubMed ID: 31330498
[TBL] [Abstract][Full Text] [Related]
7. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
[TBL] [Abstract][Full Text] [Related]
8. Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report.
Li S; Zhang Y; Sun Z; Hu J; Fang C
Medicine (Baltimore); 2018 Nov; 97(45):e12907. PubMed ID: 30407284
[TBL] [Abstract][Full Text] [Related]
9. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
Wen L; Zou X; Chen Y; Bai X; Liang T
Front Immunol; 2020; 11():2076. PubMed ID: 32973816
[TBL] [Abstract][Full Text] [Related]
10. Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism.
Patel S; Chin V; Greenfield JR
Endocrinol Diabetes Metab Case Rep; 2019 Dec; 2019():. PubMed ID: 31829972
[TBL] [Abstract][Full Text] [Related]
11. Anti-PD-L1 therapy and the onset of diabetes mellitus with positive pancreatic autoantibodies.
Way J; Drakaki A; Drexler A; Freeby M
BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 28978581
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
Kotwal A; Kottschade L; Ryder M
Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
[No Abstract] [Full Text] [Related]
13. Pembrolizumab-induced fulminant type 1 diabetes with C-peptide persistence at first referral.
Kusuki K; Suzuki S; Mizuno Y
Endocrinol Diabetes Metab Case Rep; 2020 Apr; 2020():. PubMed ID: 32478673
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
Yilmaz M
J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
[TBL] [Abstract][Full Text] [Related]
15. A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma.
Hakami OA; Ioana J; Ahmad S; Tun TK; Sreenan S; McDermott JH
Endocrinol Diabetes Metab Case Rep; 2019 Mar; 2019():. PubMed ID: 30836329
[TBL] [Abstract][Full Text] [Related]
16. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
Hong AR; Yoon JH; Kim HK; Kang HC
Front Endocrinol (Lausanne); 2020; 11():14. PubMed ID: 32047478
[TBL] [Abstract][Full Text] [Related]
18. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
Kedzior SK; Jacknin G; Hudler A; Mueller SW; Kiser TH
Am J Case Rep; 2021 Jun; 22():e931702. PubMed ID: 34185763
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes.
Tsang VHM; McGrath RT; Clifton-Bligh RJ; Scolyer RA; Jakrot V; Guminski AD; Long GV; Menzies AM
J Clin Endocrinol Metab; 2019 Nov; 104(11):5499-5506. PubMed ID: 31265074
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment.
Mengíbar JL; Capel I; Bonfill T; Mazarico I; Espuña LC; Caixàs A; Rigla M
Endocrinol Diabetes Metab Case Rep; 2019 Jul; 2019(1):. PubMed ID: 31310083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]